Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q1 2025 value amounting to $75.2 million.

  • Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) rose 5325.18% to $75.2 million in Q1 2025 from the same period last year, while for Mar 2025 it was $75.2 million, marking a year-over-year increase of 5325.18%. This contributed to the annual value of $61.0 million for FY2024, which is 2698.56% up from last year.
  • According to the latest figures from Q1 2025, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) is $75.2 million, which was up 5325.18% from $61.0 million recorded in Q4 2024.
  • Over the past 5 years, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $75.2 million during Q1 2025, and registered a low of $46.6 million during Q1 2022.
  • Its 4-year average for Shares Outstanding (Diluted Average) is $51.1 million, with a median of $47.5 million in 2023.
  • In the last 5 years, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) rose by 0.57% in 2023 and then skyrocketed by 5325.18% in 2025.
  • Over the past 4 years, Corvus Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $46.6 million in 2022, then increased by 3.16% to $48.0 million in 2023, then grew by 26.99% to $61.0 million in 2024, then grew by 23.23% to $75.2 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $75.2 million for Q1 2025, versus $61.0 million for Q4 2024 and $49.0 million for Q1 2024.